Home Reagents Clinical Chemistry Reagents Ecstasy (MDMA) assay
Quality Guranteed Fast Delivery ad for support

Ecstasy (MDMA) assay

Product Method Size Catalog Price Quantity
Ecstasy (MDMA) assay Homogenous EIA R1 2 x 16.9ml, R2 2 x 8ml DA4014 $1491.72
Shipping costs will be added at the checkout stage, click here for charges.
  • Format
    Liquid ready to use
  • Assay Range
  • Working Stability 15-25 °C
  • Working Stability 2-8 °C
    28 days
Request Kit Insert

Intended use

The MDMA assay is an in vitro diagnostic reagent. For the qualitative and semi-quantitative analysis of MDMA in human urine. The cut-off for the qualitative application is 500ng/ml. This product is suitable for use on the RX Series instruments, which includes the Rx Daytona and the Rx Imola.

This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method.

Clinical Significance

Ecstasy drugs are a group of amphetamine derivatives, including MDMA (3,4-methylenedioxymethamphetamine), MDA (3,4-methylenedixoyamphetamine), and MDEA
(3,4-methylenedioxyethylamphetamine). They are central nervous system (CNS) stimulants. At light dose ecstasy drugs produce euphoria, and increase self-awareness. However, they are popularly abused for their psychotropic effects and at high doses and become hallucinogenic and cause loss of behavior control. Toxic overdose causes depression, uncontrolled body fluid excretion, cardiac arrhythmlas, and sleep disorder. Since there is no known medical application of ecstasy drugs with high abuse potential, US DEA list both MDMA and MDA as schedule 1 drugs. After ingestion of the drug MDMA is known to metabolize to MDA by de-methylation.

Within the human body, most of the drug is eliminated through urinary excretion. Most of the urinary excretions include mono- and dihydroxy derivatives which appear as glucuronide conjugates. Detection of MDMA or its metabolites in urine indicates use of ecstasy.


The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity.

In the absence of drug in the sample, ecstasy-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. However, when free drug is present in the sample, antibody would bind to free drug; the unbound ecstasy-labeled G6PDH then exhibits its maximal enzyme activity.

Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at 340 nm.